Three flavonoid glycosides, 1 (rutin: quercetin 3-O-rutinoside), 2 (kaempferol 3-O-robinobioside) and 3 (kaempferol 3-O-rutinoside) were isolated from the subcritical water extracts of Melia azedarach leaves. Strong antiangiogenic activity of these compounds was observed in the in vivo assay using the chorioallantoic membrane (CAM) from growing chick embryos.
Angiogenesis is the process of new endothelial blood vessel development. It is essential for the growth, invasion and metastasis of most solid tumors and has become a valuable pharmacological target for cancer prevention and treatment [1a,b] . We performed in vivo experimental angiogenesis screening of plant extracts using the chorioallantoic membrane (CAM) from growing chick embryos [2] . We found that the leaf extracts of Melia azedarach L. (Meliaceae) have strong antiangiogenic activities. In particular, the activity of the leaf extracts obtained by using subcritical water was stronger than that of the extracts by using water or alcohol under atmospheric pressure (data not shown).
At present, subcritical water extraction is used for a variety of applications across various fields of study. Studies have shown its use in extracting phenolic compounds from grape pomace and potato [3a,b] . Recently, subcritical water has gained interest as an alternative solvent for the extraction of natural active compounds. We utilized this technique to identify effective antiangiogenesis compounds from medicinal plants.
M. azedarach is a large evergreen tree that is distributed from southeastern Asia to northern Australia. Previous phytochemical and pharmacological studies on the roots of the plant have revealed that it can yield limonoids with antifeedant effects [4a,b] . Furthermore, steroids, with cytotoxic effects, and flavonoids, with antioxidant activities, have been isolated from the leaves [5a,b] . However, to our knowledge, compounds exhibiting antiangiogenesis activities have not been isolated from M. azedarach.
Bioactivity-guided isolation was performed through the antiangiogenic activity of the subcritical water extracts of M. azedarach leaves by using the CAM assay. The isolation procedures are described in the Experimental section. We isolated and identified three flavonoid glycosides by NMR and MS analysis, 1 (rutin: quercetin 3-O-rutinoside), 2 (kaempferol 3-O-robinobioside) and 3 (kaempferol 3-O-rutinoside), as the active compounds from the leaf extracts of M. azedarach. Compound 1 is the main flavonoid in various plants and has been reported to possess a variety of pharmacological activities [6] . It has been previously identified from leaf extracts of M. azedarach [7] . Compound 2 has been isolated from leaves of Alternanthera brasiliana and shown to exhibit inhibitory effects on lymphocyte proliferation in vitro [8] . It has also been identified from Gynura formosana Kiamnra [9] . However, to date, no studies have reported the isolation of 2 from M. azedarach. Compound 3 has been isolated from the leaves of M. azedarach and reported to possess antioxidant activity [7] . Figure 1 shows the results of the antiangiogenic activities of 1~3 (50 μg/egg) using the CAM assay. In eggs treated with 1~3 ( Figure  1b~d ), the avascular zone was observed inside and around the silicon ring on the CAM surface. This result indicates that 1~3 inhibited angiogenesis, and the subsequent formation of the vascular network. Although 1~3 are known flavonoid glycosides, their antiangiogenic activity is reported here for the first time. We Kumazawa et al.
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also tested the antiangiogenic activity of 1~3 in vitro by using human umbilical vein endothelial cells (HUVECs), because we had observed the in vitro activity of quercetin and kaempferol, which are the aglycones of 1~3 [10] . However, 1~3 did not show any sign of the anticipated in vitro antiangiogenic activity (data not shown). It is reported that dietary flavonoid glycosides are subjected to deglycosidation by enterobacteria for absorption in the intestine [11] . However, the metabolism of flavonoid glycosides on the CAM surface was unclear, and hydrolysis of 1~3 could not be confirmed in the present study.
This study suggests that the glycosides infrom the leaves of M. azedarach exhibit antiangiogenic activity in vivo. These findings further extend the potential pharmacological effects of M. azedarach and could demonstrate its usefulness in cancer prevention and treatment.
Experimental
General: NMR experiments were performed on a Bruker BioSpin AVANCE III 400 MHz spectrometer (Billerica, MA, USA). Chemical shifts ( in ppm) were referenced to the carbon ( C 49.0) and residual proton ( H 3.30) signals of CD 3 OD. Low-resolution electrospray ionization (ESI) MS were recorded on an LCQ mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).
Plant material:
The leaves of M. azedarach were collected from Mima, Tokushima Prefecture, Japan, in July 2009. The plant was identified by Hideto Miyamoto (Medicinal Botanical Garden, University of Shizuoka, Japan). A voucher specimen was deposited at the University of Shizuoka, Japan.
Extraction and isolation:
Dried leaves of M. azedarach (2.4 kg) were extracted with subcritical water (100°C, 6 MPa, 5 min) to give a crude extract (2.2 g). This was mixed with 1 g of silica gel (Merck, Silica gel 60, Germany) and concentrated to yield dried silica gel, which was placed on the top of a silica gel column (320 mm × 30 mm i.d.) and eluted with n-hexane, EtOAc and MeOH to give 19 fractions (frs.): frs. 1~6, n-hexane/EtOAc (1:1) eluate; frs. 7~12, EtOAc/MeOH (1:1) eluate; and frs. 13~19, MeOH eluate. A total of 200 mL of each fraction was collected and evaluated by the CAM assay. Fr. 7, which showed the highest activity, was rechromatographed by preparative HPLC on a 250 mm × 20 mm i.d. ODS column (Shiseido, Tokyo, Japan) with 0.1% TFA in CH 3 CN-H 2 O (18:82) at a 10 mL/min flow rate, thus yielding the active compounds 1 (2.4 mg), 2 (2.9 mg) and 3 (4.1 mg).
CAM assay:
The CAM assay was performed as previously described [2] . In brief, fertilized chicken eggs were incubated at 37°C. On incubation day 3, a small window was opened in the shell, and 4 mL of the albumen was removed and further incubated. After 5-days, CAM was treated with various doses of the samples and incubated at 37°C for another 2 days. An appropriate volume of white emulsion was injected into CAM to clearly visualize the vascular network. Observations of the vascular networks were carried out to evaluate the antiangiogenic activity. Retinoic acid (5 nmol/egg) was used as the positive control.
